AI rebound, biotech wins, earnings week

Futures point to a rebound after last week’s sharp tech/AI selloff (Nasdaq Composite -4.5% for the week, largest since late June; S&P -2%). AI-linked names are leading the bounce ($NVIDIA(NVDA.US) +1–2%, $Broadcom(AVGO.US) +2%+, semis and memory groups higher), helped by lower oil and modestly easier Treasury yields.

The 10-year is around 5.08–5.09%. Brent is down ~1.8–2% to the mid-$107s after President Trump waived key provisions of the Graham Act Russia sanctions package (signed into law last month and set to take effect this week), citing national interest and efforts to ease energy prices ahead of midterms. Zelensky has criticized the move.

Risks remain: another tanker mine hit reported in the Strait of Hormuz, with shipping/insurance costs still elevated. Fed Chair Kevin Warsh offered no rate signal last week; markets price a high probability (~72–85%) of a hold at the Oct 27–28 meeting after September’s hike, with a December hike still possible. Higher-for-longer rates remain a overhang for AI infrastructure financing. Today’s main data point is the NAHB Housing Market Index at 10 a.m. ET (prior 32).

AI Infrastructure & Semis: Dip-Buying After Financing Scare

Last week’s pressure on AI capex sustainability, data-center debt, and higher rates is reversing in premarket. Neoclouds are notable: $Coreweave(CRWV.US) +6%+ after Goldman Sachs upgraded it to Buy from Neutral (PT cut to $106 from $139, still implying substantial upside). GS cites tighter supply supporting ARR per MW and unlevered IRR, differentiation versus peers, and overestimation of capital costs by the market after the stock’s recent drop (~43% from mid-August, -24% in five days).

$Nebius(NBIS.US) and $IREN(IREN.US) are also higher in sympathy. Memory names ($Micron Tech(MU.US), $Sandisk(SNDK.US) and related) are rebounding as part of the broader semi complex. FinTwit chatter frames this as selective buy-the-dip in the hardest-hit AI infra names, with the key test being follow-through and whether earnings this week provide monetization evidence rather than just more spending commitments. One note of caution circulating is that financing spreads had widened and nothing fundamental changed overnight.

$Intel(INTC.US) is up ~4% after JPMorgan upgraded it to Neutral from Underweight (PT unchanged at $85). The firm sees more balanced risk/reward after a ~36% drop from the June peak. Since Lip-Bu Tan’s appointment as CEO, execution has improved in core client/data-center compute and next-gen manufacturing (yields, foundry compatibility, advanced packaging). JPMorgan also points to agentic AI workloads (CPU-intensive) and tight leading-edge silicon supply as potential drivers of positive EPS revisions into 2027; its 2028 EPS is ~15% above consensus. This is a classic “valuation reset + operational progress” catalyst after prior underperformance versus the group.

Biotech Binary Outcomes

$Disc Medicine(IRON.US) (Disc Medicine) is surging 40%+ (and higher in some prints) after announcing that its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP, including XLP) met all primary and secondary endpoints. Co-primaries: 41.4% reduction in whole-blood metal-free PPIX vs placebo (p<0.0001) and +12.2 hours average monthly time in light without pain in month 6 (p=0.0010). Secondary endpoints on phototoxic reactions and cumulative light tolerance were also hit. The drug was generally well-tolerated (dizziness most common TEAE). Company plans to resubmit NDA by year-end 2026 with a potential mid-2027 FDA decision. This directly addresses the prior Complete Response Letter. Webcast this morning at 8 a.m. ET. Rare-disease positive readout with clear regulatory path is a classic high-conviction catalyst.

$EyePoint(EYPT.US) (EyePoint) is collapsing ~80%+ after the second Phase 3 LUCIA trial of Duravyu in wet AMD failed the primary non-inferiority endpoint versus Regeneron’s Eylea (vision improved but not enough to meet the bar). Company is ending the wet AMD pivotal trials early, cutting ~53% of its workforce (annualized savings ~$30M), and shifting focus to diabetic macular edema (Phase 3 data expected Q4 2027). Cash was ~$118M as of Sept 30. This is the second miss (prior failure in August triggered a large drop); capital preservation and pipeline pivot are the near-term story, with high residual binary risk.

Software & Observability

$Datadog(DDOG.US) is up ~3.6% after Bernstein SocGen upgraded it to Outperform from Market Perform and raised the PT sharply to $350 from $237. The firm is more constructive on AI demand strength after previously flagging concerns around a large “Born in AI” customer contract downsizing and traditional customer softness. AI observability remains a structural tailwind narrative on FinTwit for infrastructure software that owns critical telemetry and context layers.

Earnings Calendar This Week (Catalyst Heavy)

Monday is relatively light (already includes $Cleveland Cliffs(CLF.US), which reported Q3 adjusted EPS $0.28 beating ~$0.24, revenue $5.61B, adjusted EBITDA $612M above the $575M guide, and a constructive Q4/2027 outlook; stock +13% pre). The real tests arrive mid-week:

- Tuesday: $Netflix(NFLX.US), $SpaceX(SPCX.US) (SpaceX), $General Motors(GM.US), $GE Aerospace(GE.US), $RTX(RTX.US), others.

- Wednesday: $Meta Platforms(META.US), $Tesla(TSLA.US), $IBM(IBM.US), $Lam Research(LRCX.US), $Texas Instruments(TXN.US) and more.

- Thursday/Friday: $Procter & Gamble(PG.US), $Lockheed Martin(LMT.US), $Western Digital(WDC.US), $American Express(AXP.US), etc.

After last week’s AI financing and rate-driven selloff, guidance and commentary on AI spend ROI, capex intensity, and demand will be closely watched. Options implied moves on several names are elevated. A clean beat-and-raise cycle from the larger names would reinforce the premarket rebound; weak monetization language could reverse it quickly.

Other Notes

- Oil remains geopolitically sensitive despite the Russia waiver; Hormuz incidents continue to create noise without fully clearing.

- Broader semi lead-time and pricing data from prior weeks (passives, power, analog) had been supportive of the upcycle; the rebound today is consistent with that backdrop but rate sensitivity is the new variable.

- Pre-market volume leaders include several AI/semi names plus the biotech extremes noted above. Selective positioning is the prevailing FinTwit posture: favor names with specific catalysts (upgrades, data, earnings) over pure beta into the print week.

NFA / DYOR. This is not financial advice. Markets move on new information; do your own research and manage risk accordingly.